Adverse events associated with biologics approved for gMG use

his dataset supports a real-world pharmacovigilance study that evaluates and compares adverse events (AEs) associated with five biologics—efgartigimod, rozanolixizumab, eculizumab, ravulizumab, and zilucoplan—used in the treatment of generalized myasthenia gravis (gMG). The data were extracted from the FDA Adverse Event Reporting System (FAERS) covering the period from Q3 2023 to Q4 2024. Disproportionality analysis (PRR, ROR, IC, EBGM) and multivariable logistic regression were performed to identify AE signals and risk factors for hospitalization. The dataset includes de-duplicated AE reports, signal detection results, and regression analysis inputs. This resource can be used to support further safety assessments and comparative studies of gMG biologics.